

Influenza Session

Robert L. Atmar, MD
Chair, Influenza Work Group

Advisory Committee on Immunization Practices
February 24, 2020

Influenza Work Group

ACIP Members

Robert Atmar (Chair)

Kevin Ault

Hank Bernstein

Peter Szilagyi

Keipp Talbot

***Ex Officio* Members**

Michael Cooper (NIH)

Cynthia Nolletti (FDA)

Chris Roberts (NIH)

Susan Wollersheim (FDA)

Consultants

Ed Belongia

Jeff Duchin

Wendy Keitel

Jamie Loehr

Mark Mulligan

Kathy Neuzil

Liaison Representatives

Sarah Coles (AAFP)

Buddy Creech (PIDS)

Sarah Despres (Consumer Representative)

Sandra Fryhofer (ACP; AMA)

Ian Gemmill (NACI)

Denise Jamieson (ACOG)

Marie-Michèle Léger (AAPA)

Susan Lett (CSTE)

Flor Munoz (AAP)

William Schaffner (NFID)

Rob Schechter (AIM)

Ken Schmader (AGS)

Patsy Stinchfield (NAPNAP)

Tamara Sheffield (AHIP)

Kelsey Young (NACI)

Matthew Zahn (NACCHO)

Recap of Influenza Session, October 2019

- Overview of early 2019-20 season influenza activity
- Presentation from Sanofi Pasteur of pre-licensure study of quadrivalent high-dose inactivated influenza vaccine, Fluzone High-Dose Quadrivalent
 - Subsequently licensed by FDA November 4, 2019
- Discussion of planned systematic review of influenza vaccines for older adults

Recent Work Group Discussion

- Presentation and discussion of preliminary safety results from a comparative study of adjuvanted and high-dose inactivated vaccines among persons 65 years of age and older
- Presentation from Seqirus of pre-licensure study of quadrivalent adjuvanted inactivated influenza vaccine, Fluvad Quadrivalent
 - Licensed by FDA February 21, 2020
- Selection of efficacy/effectiveness and safety outcomes for review of influenza vaccines for older adults

Agenda Overview

- **Older Adult (65+) Adjuvanted Quadrivalent Influenza Vaccine (aIIV4) Phase III Trial**
 - Dr. Gregg Sylvester (Seqirus)
- **2019-20 U.S. Influenza Surveillance Update**
 - Ms. Lynnette Brammer, CDC/NCIRD
- **Interim Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness against Medically Attended Influenza from the US Flu VE Network**
 - Dr. Brendan Flannery, CDC/NCIRD
- **Safety of Adjuvanted vs. High-Dose Inactivated Influenza Vaccines in Older Adults: Preliminary Safety Results**
 - Dr. Kenneth Schmader, Duke University Medical Center
- **Summary and Work Group Considerations**
 - Dr. Lisa Grohskopf, CDC/NCIRD